{"id":"06763","slug":"novel-mouse-model-for-dent--06763","source":{"id":"06763","dataset":"techtransfer","title":"Novel Mouse Model for Dent Disease Type 1 Research","description_":"

A novel knockout mouse model has been developed that recapitulates the hallmark features of Dent disease type 1, a rare X-linked kidney disorder caused by loss of function of the chloride/proton antiporter ClC-5. This genetically distinct model provides researchers with a powerful and validated platform to investigate kidney disease mechanisms and explore potential therapeutic interventions.

Description

This mouse model carries a unique base pair deletion within the Clcn5 gene that spans part of exon and the adjacent intron junction, disrupting normal splicing and causing early termination of the ClC-5 protein. The resulting loss of ClC-5 antiporter function faithfully reproduces the pathological hallmarks of Dent disease type 1, including tubular proteinuria, impaired endocytic uptake of filtered proteins in kidney proximal tubule cells, and progressive kidney dysfunction.\r\n\r\nWhat distinguishes this model from previously available Dent disease mouse lines is its novel mutation strategy, which differs from all existing published ClC-5 knockout models. Studies using this model have already revealed mechanistic insights at the cellular level — specifically, that loss of ClC-5 impairs endosomal acidification and delays early endosome maturation, reducing the surface expression and recycling of megalin and cubilin, the key receptors responsible for recovering filtered proteins in the kidney. The model has further demonstrated segment-specific differences in receptor loss along the proximal tubule axis, with greater reductions observed in the S2 subsegment, with implications for understanding disease progression.

Applications

- Preclinical research tool for elucidating pathophysiological mechanisms of Dent disease type 1, especially the role of ClC-5 in endosomal trafficking within kidney proximal tubule cells.\r
- Platform for evaluating the efficacy of potential therapeutic interventions targeting endosome maturation and acidification defects to restore protein reabsorption in Dent disease.\r
- Model for investigating genotype-phenotype correlations and regional segment-specific renal pathology in experimental nephrology.\r
- Resource for studying extra-renal manifestations associated with ClC-5 dysfunction and their molecular underpinnings.\r
- Validation system for in vitro mechanistic studies, bridging cellular-level findings with whole-organism physiology through integrated biochemical and imaging data.

Advantages

- Genetic Uniqueness: The specific 189 base pair deletion provides a precise, early termination mutation distinct from existing models, enabling refined investigations into ClC-5 loss-of-function effects.\r
- Pathophysiological Relevance: Accurately replicates the molecular and cellular mechanisms implicated in Dent disease, including impaired endosome maturation and defective protein receptor recycling.\r
- Segment-Specific Insights: Reveals subsegmental heterogeneity within the proximal tubule, enhancing understanding of spatial disease progression and potential tissue-specific therapeutic targeting.\r
- Integrated Methodology: Combines in vivo phenotyping with robust in vitro biochemical and imaging techniques alongside predictive mathematical modeling to generate comprehensive data.\r
- Therapeutic Development Support: Provides an established, validated platform to screen and assess candidate treatments aimed at improving endocytic function and mitigating proteinuria.\r
- Research Community Accessibility: Rights and intellectual property are secured to facilitate dissemination and collaborative research efforts, promoting translational applications.

Invention Readiness

The ClC-5 knockout mouse model has been fully developed and subjected to extensive validation including genetic characterization, phenotypic assessment, and mechanistic studies integrating biochemical and imaging data. The model effectively reproduces Dent disease pathology, confirming its utility for investigative and preclinical applications. Ongoing research aims to expand understanding of disease mechanisms and to evaluate targeted interventions; further longitudinal studies will elucidate progression dynamics and treatment impacts. Overall, this technology is mature for adoption by research laboratories focused on renal disease and therapeutic innovation.

IP Status

Research Tool

Related Publication(s)

Shipman, Katherine E., et al. "Impaired endosome maturation mediates tubular proteinuria in dent disease cell culture and mouse models." Journal of the American Society of Nephrology 34.4 (2023): 619-640. https://doi.org/10.1681/asn.0000000000000084

","tags":["Genetics","Rare disease"],"file_number":"06763","collections":[{"key":517,"name":"Cardiometabolic"}],"meta_description":"Novel ClC-5 knockout mouse replicates Dent disease type 1, enabling mechanistic studies and preclinical therapeutic testing.","image_url":"","apriori_judge_output":"{\"scores\":{\"novelty\":4.0,\"potential_impact\":4.0,\"readiness\":3.0,\"scalability\":2.0,\"timeliness\":3.0},\"weighted_score\":3.65,\"risks\":[\"Model is a single genetic alteration in mice; cross-species translation may be limited.\",\"Readiness at TRL 4; further validation needed for regulatory/commercial use.\",\"Scalability limited by reliance on animal model; may not scale to high-throughput screens.\"],\"one_sentence_take\":\"A novel, functionally disruptive Clcn5 knockout mouse offers meaningful mechanistic insights and preclinical testing utility for Dent disease type 1, but translational and scalability hurdles temper its readiness for broad commercialization.\"}","lead_inventor_name":"Ora Weisz","lead_inventor_dept":"Med-Medicine","technology_type":"Life Science Research Tool","technology_subtype":"Animal Model","therapeutic_areas":["Nephrology"],"therapeutic_indications":["Rare Renal Diseases","Chronic Kidney Disease (CKD)"],"custom_tags":[],"all_tech_innovators":["Katherine Elizabeth Shipman","Ora Anna Weisz"],"date_submitted":"2024-06-04","technology_readiness_level":"4. Prototype testing and refinement"},"highlight":{},"matched_queries":null,"score":0.0}